Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537584 · ClinicalTrials.gov registry record · Phase 4
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
A Phase 4 study of Major Depressive Disorder, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 133
- Enrollment target
- 1
- Study location
NCT05537584 is a Phase 4 study of Major Depressive Disorder that has completed, run by Mclean Hospital. The registered enrollment target is 133 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05537584, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 133 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
Conditions Studied
Interventions
- DRUG Sertraline
- DRUG Bupropion
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05537584
The ClinicalTrials.gov registry entry for NCT05537584 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (65% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sertraline is the first listed.
NCT05537584 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05537584 about?
NCT05537584 is a clinical study titled "SMART Trial to Predict Anhedonia Response to Antidepressant Treatment". The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
What is the current status of trial NCT05537584?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 133 participants. The study started on 2022-09-30. Estimated completion is 2025-08-26.
What conditions does trial NCT05537584 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05537584?
The interventions under investigation include: Sertraline (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT05537584?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537584 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.